Health care stocks were mixed pre-bell Monday as the iShares Biotechnology ETF (IBB) was up 0.2% and the Health Care Select Sector SPDR Fund (XLV) was 0.1% lower recently.
PTC Therapeutics (PTCT) shares advanced by over 17% after the company said it signed an exclusive global license and collaboration agreement for its PTC518 Huntington's disease program with a subsidiary of Novartis (NVS), and will receive a $1 billion upfront payment.
Zai Lab (ZLAB) and NovoCure (NVCR) said their phase 3 trial evaluating TTFields along with gemcitabine and nab-paclitaxel as a treatment for unresectable, locally advanced pancreatic adenocarcinoma achieved its primary endpoint, demonstrating a "statistically significant" improvement in median overall survival. NovoCure shares rose past 45% premarket.
Olema Pharmaceuticals (OLMA) shares were nearly 9% higher after the company said it has launched a clinical trial collaboration and supply agreement with Novartis (NVS) for a frontline metastatic breast cancer treatment.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。